All In Biotech

NDA 021539 · Apotex

Acetadote

Acetylcysteine · Intravenous · Antidote; Antidote for Acetaminophen Overdose; Mucolytic

Priority reviewOrphan

Last checked: Nov 21, 2026Latest source record: Jul 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

Jan 23, 2004

Approved uses

2

Original approval plus efficacy supplements

Registered trials

587

113 Phase 3, 40 recruiting

FAERS reports

9,625

8,567 serious, 1,796 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 31, 2025.

Acetylcysteine Injection is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in adults and pediatric patients who weigh 5 kg or greater with acute ingestion or from repeated supratherapeutic ingestion (RSI). Acetylcysteine Injection is an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in adults and pediatric patients who weigh 5 kg or greater with acute ingestion or from repeated supratherapeutic ingestion (RSI) ( 1 ).

Mechanism: Acetylcysteine has been shown to reduce the extent of liver injury following acetaminophen overdose. Acetaminophen doses of 150 mg/kg or greater have been associated with hepatotoxicity. Acetylcysteine probably protects the liver by maintaining or restoring the glutathione levels, or by acting as an alternate substrate for conjugation with, and thus detoxification of, the reactive metabolite of acetaminophen.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 26, 2024 Supplement 19 · Efficacy OrphanLabelLetter
  • Jan 23, 2004 Original approval · Type 3 - New Dosage Form · priority review OrphanReviewLetterLabel
1 products under this application
  • ACETADOTE · ACETYLCYSTEINE 6GM/30ML (200MG/ML) · INJECTABLE, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Acetylcysteine" as an intervention, any sponsor and status, largest first.

All 587 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea800
  • off label use680
  • drug ineffective679
  • pneumonia651
  • pyrexia520
  • fatigue468
  • nausea453
  • diarrhoea379
  • vomiting342
  • death333
  • cough323
  • hypertension318

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004176
2005136
2006154
2007126
2008194
2009190
2010270
2011284
2012281
2013166
2014204
2015285
2016288
2017273
2018430
2019517
2020597
2021774
2022799
2023929
2024872
2025951
2026728

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Acetadote* (Acetylcysteine*) · HCPCS J0132

2024 spending

$679

Beneficiaries

190

769 claims

Per beneficiary

$4

2024 ASP limit $0.65 per unit

View as table
YearSpending
2020$333
2021$121
2022$281
2023$396
2024$679

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,355 on PubMed

Sponsor: Apotex

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.